Find Ecamsule manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 5 FDA Orange Book

5 FDF Dossiers
5 FDA Orange Book

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 6 SPI Pharma, 4 DKSH, 1 Pharm-RX Chemical, 1 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 4 Actylis, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 5 BASF, 12 Corel Pharma Chem, 1 Finar, 4 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 17 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 3 Lubrizol Life Science Health, 3 Microlex e.U, 1 Novo Excipients, 1 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 4 Roquette, 6 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives, 17 Controlled & Modified Release, 16 Topical, 12 Film Formers & Plasticizers, 10 Thickeners and Stabilizers, 8 Co-Processed Excipients, 7 Direct Compression, 6 Lubricants & Glidants, 6 Fillers, Diluents & Binders, 5 Empty Capsules, 5 API Stability Enhancers, 5 Granulation, 4 Parenteral, 4 Vegetarian Capsules, 4 Solubilizers, 4 Emulsifying Agents, 3 Rheology Modifiers, 2 Chewable & Orodispersible Aids, 2 Taste Masking, 2 Coloring Agents, 1 Disintegrants & Superdisintegrants

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 2 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
2 NEWS #PharmaBuzz

MARKET PLACE

1 APIs

marketPlace
1 APIs

REF. STANDARDS & IMPURITIES

4 USP , 8 Others

otherSolutions
4 USP
8 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

98 RELATED EXCIPIENT COMPANIES

166EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 90457-82-2, 92761-26-7, Terephthalylidene dicamphor sulfonic acid, Schembl119994, Amy215, [2-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid

Molecular Formula

C₂₈H₃₄O₈S₂

Molecular Weight

562.7 g/mol

InChI Key

HEAHZSUCFKFERC-LRVMPXQBSA-N

1 2D Structure

Ecamsule

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(3E)-3-[[4-[(Z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid

2.1.2 InChI

InChI=1S/C28H34O8S2/c1-25(2)21-9-11-27(25,15-37(31,32)33)23(29)19(21)13-17-5-7-18(8-6-17)14-20-22-10-12-28(24(20)30,26(22,3)4)16-38(34,35)36/h5-8,13-14,21-22H,9-12,15-16H2,1-4H3,(H,31,32,33)(H,34,35,36)/b19-13-,20-14+

2.1.3 InChI Key

HEAHZSUCFKFERC-LRVMPXQBSA-N

2.1.4 Canonical SMILES

CC1(C2CCC1(C(=O)C2=CC3=CC=C(C=C3)C=C4C5CCC(C4=O)(C5(C)C)CS(=O)(=O)O)CS(=O)(=O)O)C

2.1.5 Isomeric SMILES

CC1(C\2CCC1(C(=O)/C2=C/C3=CC=C(C=C3)/C=C\4/C5CCC(C4=O)(C5(C)C)CS(=O)(=O)O)CS(=O)(=O)O)C

2.2 Synonyms

2.2.1 MeSH Synonyms

1. 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic Acid)

2. Mexoryl Sx

3. Terephthalylidene Dicamphor Sulfonic Acid

2.2.2 Depositor-Supplied Synonyms

1. 90457-82-2

2. 92761-26-7

3. Terephthalylidene Dicamphor Sulfonic Acid

4. Schembl119994

5. Amy215

6. [2-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic Acid

2.3 Create Date

2006-04-28

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₃₄O₈S₂
Molecular Weight	562.7 g/mol
XLogP3	3.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Exact Mass	562.16951039 g/mol
Monoisotopic Mass	562.16951039 g/mol
Topological Polar Surface Area	160 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	1230
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	4
Defined Bond Stereocenter Count	2
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Therapeutic Uses

Ultraviolet screen

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 639

/EXPL THER/ The aim of this study was to determine, for regulatory purposes, the potential of Mexoryl SX, a broad UVA absorber that also absorbs to some extent in the UVB, to modify the UV radiation (UVR)-induced murine skin tumor development and growth. Skh-hr1 mice were exposed to solar-simulated UVR 5 days per week for 40 weeks. Two control groups were irradiated without topical application, three groups received a sunscreen preparation containing either the UVA absorber, Mexoryl SX at 5 or 10% concentration, or a filter that absorbs principally in the UVB, 2-ethylhexyl-p-methoxycinnamate (2-EHMC) at 5% concentration, introduced as a comparator test article. Sunscreen application was performed before UVR exposure 3 days per week and after UVR exposure on the other 2 days (consistent with the design of a standard photocarcinogenesis safety test). Two different weekly UVR doses were administrated: the lower dose was given to one group of unprotected animals, whereas the higher dose was administrated to the other unprotected group and to the three sunscreen-treated groups. The two UVR control groups demonstrated a UVR-dependent response for cumulative tumor prevalence, tumor yield and median latent period. Neither concentration of Mexoryl SX increased the probability of tumor development; consistent with the principles for safety testing, this provides evidence in that it is safe for use in sunlight. Although this study was explicitly designed as a safety test, the results also provide some clues about the efficacy of Mexoryl SX in decreasing the probability of tumor development. Topical administration of Mexoryl SX, at both concentrations, resulted in a 6 week delay in the median latent period compared to high UVR controls, whereas 5% 2-EHMC delayed the median latent periods only by 2 weeks. Tumor prevalence and yield show the same efficacy differences between the two sunscreen ingredients. Tumor protection factors were calculated from these results and found to be equal to 2.4 for the two preparations containing Mexoryl SX and to 1.3 for the 5% 2-EHMC preparation. These findings illustrate the efficacy of Mexoryl SX in preventing UVR-induced carcinogenesis.

PMID:8863475 Fourtanier A; Photochem Photobiol 64 (4): 688-93 (1996)

/EXPL THER/ In a previous study on the hairless mouse it was shown that sub-erythemal doses of pure UV-A enhanced the numerous changes normally observed during chronological aging. A new sunscreen (a bis-benzylidene campho sulfonic acid derivative) has been synthesized in our research laboratory (lambda max: 345 nm, epsilon: 47,000). Its photoprotective properties against UV-A induced damages were assessed in our mouse model. Three-month-old albino hairless mice were exposed for 1 y to suberythemal doses (35 J/sq cm) of UV-A obtained from a xenon source filtered through a WG 345 filter. One group of animals was exposed untreated, the other received a formulation containing 5% of the sunscreen prior to irradiation. At the end of the study the cutaneous properties of protected mice were compared to those of unprotected animals and to 3 and 15-month-old unirradiated controls. We found that the visible changes induced by UV-A irradiation were mainly sagging and wrinkling. Histological and electron microscopic alterations consisted of hyperkeratosis, increased density of elastic fibers with alteration of fiber orientation and increased glycosaminoglycan deposits. Biochemical changes consisted of decreases in total collagen and collagen hydroxylation and increases in both collagen III/I + III ratio and fibronectin biosynthesis. All these changes were reduced or abolished by the sunscreen.

PMID:1320278 Fourtanier A et al; Photochem Photobiol 55 (4): 549-60 (1992)

/EXPL THER/ BACKGROUND/PURPOSE: Exposure to ultraviolet (UV) radiation increases skin pigmentation and usually results in an even darkening of the skin. However, it may also occasionally lead to the development of hyperpigmented lesions due to a local overproduction of pigment. Skin pigmentation is induced both by UVB and UVA rays. METHODS: The in vivo protection by sunscreens against pigmentation was studied using the determination of a level of protection against pigmentation based on the standardized sun protection factor (SPF) test method. The method includes delayed UVB and UVA pigmentations. The level of prevention against pigmentation was determined 7 days after exposure to solar-simulated radiation by visual assessment. It was calculated using the ratio of the minimal pigmenting dose on protected skin to the minimal pigmenting dose on unprotected skin. Broadspectrum UVB/UVA filters, Mexoryl SX and Mexoryl XL, and complete formula were tested. RESULTS: Protection against pigmentation correlates with the concentration of Mexoryl SX. The levels of protection obtained show a synergetic effect of Mexoryl SX when associated with Mexoryl XL. When different products having the same SPF (same protection against erythema) and different levels of UVA protection are compared, only sunscreen products with a high level of UVA protection show a similar level of protection against sunburn and pigmentation. Products with low UVA protection have a lower capacity of preventing induced pigmentation compared with their efficacy against erythema. CONCLUSIONS: These studies have evidenced that SPF determination was not sufficient to account for the efficiency in preventing pigmentation and that UVA protection was an essential part of this prevention.

PMID:15379874 Moyal D; Photodermatol Photoimmunol Photomed 20 (5): 243-7 (2004)

For more Therapeutic Uses (Complete) data for Terephthalylidene dicamphor sulfonic acid (6 total), please visit the HSDB record page.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Sunscreening Agents

Chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation. (See all compounds classified as Sunscreening Agents.)

5.2 Absorption, Distribution and Excretion

The potential human health risk of UV filters depends on their toxicity and the human systemic exposure which is a function of the extent of percutaneous absorption of the topically applied substance into the human organism. Using a 'mass balance' approach, a study was designed to investigate the systemically absorbed dose of [(14)C]-Mexoryl SX((R)) in humans after topical application of a typical sunscreen emulsion. In addition, to assess the correlation with in vitro experiments, the percutaneous absorption of this UVA filter through isolated human skin was measured under identical exposure conditions. When applied in vivo for a period of 4 hr, 89-94% of the applied radioactivity was recovered from the wash-off samples. In urine samples, the radioactivity slightly exceeded background levels and corresponded maximally to 0.014% of the topically applied dose. No radioactivity was measured in blood or feces sampled up to 120 hr after application. In vitro, 24 hr after a 4-hour application, [(14)C]-Mexoryl SX remained primarily on the skin surface. The mean in vitro absorption over 24 hr, adding up the amounts found in the dermis and receptor fluid, was 0.16% of the applied dose. It is concluded from the in vivo pharmacokinetic results that the systemically absorbed dose of [(14)C]-Mexoryl SX is less than 0.1%. The order of magnitude of this value correlates well with the corresponding in vitro data which overestimate the in vivo results as previously observed with other hydrophilic compounds. This study demonstrates that, under realistic exposure conditions, the human systemic exposure to this UVA filter is negligible and poses no risk to human health.

PMID:14528058 Benech-Kieffer F et al; Skin Pharmacol Appl Skin Physiol 16 (6): 343-55 (2003)

An in vivo method in humans using radioactive terephthalylidene dicamphor sulfonic acid ((14)C site not specified) showed an absorption determined up to 24 hours after a 4-hours exposure to 0.16% of the applied dose.

The Danish Environmental Protection Agency. Survey and health assessment of UV filters. p.170 (2015)

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

Controlled & Modified Release

Topical

Film Formers & Plasticizers

Thickeners and Stabilizers

Co-Processed Excipients

Direct Compression

Lubricants & Glidants

Fillers, Diluents & Binders

Empty Capsules

API Stability Enhancers

Granulation

Parenteral

Vegetarian Capsules

Solubilizers

Emulsifying Agents

Rheology Modifiers

Chewable & Orodispersible Aids

Taste Masking

Coloring Agents

Disintegrants & Superdisintegrants

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

USP

Others

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Post Enquiry

Market Place

Find Ecamsule manufacturers, exporters & distributors on PharmaCompass

Ecamsule

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers

1 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers

5 FDA Orange Book

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

6 SPI Pharma

4 DKSH

1 Pharm-RX Chemical

1 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 ACG Worldwide

4 Actylis

2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

5 BASF

12 Corel Pharma Chem

1 Finar

4 Gangwal Chemicals

4 Ideal Cures Pvt Ltd

17 Kerry

3 Kima Chemical

6 Lonza Capsugel

3 Lubrizol Life Science Health

3 Microlex e.U

1 Novo Excipients

1 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

4 Roquette

6 Seppic

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Sigachi Industries

2 The Dow Chemical Company

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives

17 Controlled & Modified Release

16 Topical

12 Film Formers & Plasticizers

10 Thickeners and Stabilizers

8 Co-Processed Excipients

7 Direct Compression

6 Lubricants & Glidants

6 Fillers, Diluents & Binders

5 Empty Capsules

5 API Stability Enhancers

5 Granulation

4 Parenteral

4 Vegetarian Capsules

4 Solubilizers

4 Emulsifying Agents

3 Rheology Modifiers

2 Chewable & Orodispersible Aids

2 Taste Masking

2 Coloring Agents

1 Disintegrants & Superdisintegrants

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

2 NEWS #PharmaBuzz

MARKET PLACE

1 APIs

REF. STANDARDS & IMPURITIES

4 USP

8 Others

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS